# Logos Capital

Logos Capital is an Asset Manager based in San Francisco, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** San Francisco, United States
- **Region:** North America
- **Address:** San Francisco, CA, United States
- **Founded:** 2019
- **Assets under management:** Undisclosed
- **Website:** www.logoscapital.com

## Regulatory record

- **Reports private funds:** No

## About

Logos Capital is dedicated to advancing healthcare through disciplined, data-driven investment in biotechnology. Our mission is to identify and fund life-changing therapeutics that will generate superior long-term returns for investors. Our approach involves thorough event tracking, clinical trial underwriting, and proactive risk management to understand the intrinsic value of each opportunity.

## Sectors

- Healthcare Services
- Digital Health
- AI/ML

## People

- Arsani William — Founder, Managing Partner & Portfolio Manager

## Questions

### Who makes investment decisions at Logos Capital?

Arsani William, the firm's founder and managing partner, is the sole portfolio manager. He is a medical doctor by training and made the call to leave a prior healthcare investing role to launch Logos in 2019. The structure is intentionally flat — there is no investment committee or multi-PM risk-book system. William's clinical judgment and proprietary bioinformatics pipeline drive every position the fund takes.

### What does Logos Capital actually invest in?

Logos runs a long-biased public-equity portfolio concentrated in biotechnology and precision-medicine companies. The firm targets small- to mid-cap names with near-term binary catalysts: Phase III trial results, FDA panel votes, or label-expansion decisions. Sector concentration spans oncology, rare disease, immunology, and AI-enabled drug discovery platforms. It does not appear to run a short book of meaningful size.

### How is Logos Capital different from other biotech hedge funds?

The structural differentiator is that the founder and sole decision-maker is a physician who actively interprets clinical-trial data himself, rather than delegating to a team of PhD analysts feeding a committee. Most large biotech funds — Baker Bros, Perceptive, RTW — deploy teams of scientists and distribute risk across multiple sub-portfolios. Logos bets that one clinician-investor, reading the same data as everyone else, can reach a contrarian conclusion faster. That is the entire strategy.

## Related profiles

- [Logiver](https://altss.com/profile/logiver)
- [Logo Ventures](https://altss.com/profile/logo-ventures)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/logos-capital

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology